ClinicalTrials.gg
CompletedNCT02384460Updated Apr 9, 2020Results posted

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

A Phase 3 interventional study of SD-101-6.0 cream and Placebo (SD-101-0.0) cream in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Completed at 38 sites in 13 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2020-04-09.

Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.

Enrollment
2nd of 37
169 · median 16
Started
2015
with 1 other
Phase 3
8 of 42
1 open now
Registered
10th of 42
by date
Lead sponsor
4 of 42
Scioderm, Inc.

Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 10th registered.

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.

Browse Epidermolysis Bullosa studies →

Open to participants now

10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 1 Month and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Epidermolysis Bullosa with a site in United States, or all of them as a file.
02

Study summary

The aim was to assess the efficacy and safety of SD-101-6.0 cream versus Placebo (SD-101-0.0) cream in the treatment of skin lesions in participants with Epidermolysis Bullosa. Funding Source - United States Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD).

Read the detailed description

This was a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SD-101-6.0 cream versus placebo (SD-101-0.0) cream on skin lesions in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa. Epidermolysis Bullosa is a rare group of inherited disorders that typically manifest at birth as blistering and lesion formation on the skin in response to little or no apparent trauma. In this study, SD-101-6.0 cream or placebo (SD-101-0.0) cream was to be applied topically, once a day to the entire body for a period of 90 days. Participants had 1 target wound selected at baseline by the investigator. The selected target wound was required to have been present for at least 21 days. Photographic confirmation of the target wound location was collected at baseline, and the picture saved from the first visit was used to confirm location of the target wound at subsequent visits. The participant returned to the study site for Visit 2 (approximately 14 days from baseline), Visit 3 (approximately 30 days from baseline), Visit 4 (approximately 60 days from baseline), and Visit 5 (approximately 90 days from baseline) to have the target wound assessed for the level of healing. In addition, itching, pain, body surface area, target wound closure, and scarring of healed target wound were assessed at each visit. The ARANZ SilhouetteStar™ was used to measure the target wound at all visits.

03

Conditions studied

  • Epidermolysis Bullosa

Browse trials for

Keywords

  • Amicus Therapeutics
  • Scioderm, Inc.
  • Simplex
  • Recessive Dystrophic
  • Junctional non-Herlitz
  • Epidermolysis Bullosa
  • SD-101 6%
  • SD-101-6.0
  • Allantoin 6%
  • Zorblisa
04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • form signed by the participant or participant's legal representative; if the participant was under the age of 18 but capable of providing assent, signed assent from the participant.
  • Participant (or caretaker) must have been willing to comply with all protocol requirements.
  • Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.
  • Participant must have had 1 target wound (size 10 to 50 cm\^2) at study entry.
  • Participants 1 month and older.
  • Target wound must have been present for at least 21 days.

Exclusion criteria

Exclusion Criteria:

  • Participants who did not meet the entry criteria outlined above.
  • Selected target wound did not have clinical evidence of local infection.
  • Use of any drug within the 30 days before enrollment.
  • Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.
  • Use of systemic or topical steroidal therapy within the 30 days before enrollment. (Inhaled and ophthalmic drops containing steroids were allowed).
  • Use of systemic antibiotics within the 7 days before enrollment.
  • Current or former .
  • Arterial or venous disorder resulting in ulcerated lesions.
  • Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at screening and every 30 days until the final visit for female participants of ).
  • Females of childbearing potential who were not abstinent and not practicing a medically acceptable method of .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    SD-101-6.0 cream

    SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days

    Drug: SD-101-6.0 cream

  • Placebo comparator
    Placebo (SD-101-0.0) cream

    SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days

    Drug: Placebo (SD-101-0.0) cream

Interventions

  • applied topically once a day for 90 days

    Also known as: SD-101

  • DrugPlacebo (SD-101-0.0) cream

    applied topically once a day for 90 days

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Time To Complete Target Wound Closure Within 3 Months

    Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Time to target wound closure was measured from the date of the first administration of the study drug to the date of target wound closure. Participants were censored if they did not have a response within 3 months, or withdrew earlier before the confirmation of their target wound closing. This primary end point displays the mean time to complete target wound closure, analyzed using a Kaplan-Meier approach.

    Time frame: From baseline to Month 3 visit

  2. The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months

    Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Participants were considered responders if they experienced complete wound closure at the Week 2 or Months 1, 2, or 3 visits. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits. This primary end point displays the percentage of participants from the ITT population who had complete target wound closure by the end of the study period (that is, 3 months). Analysis was performed on participants with post-baseline wound closure data.

    Time frame: From baseline to Month 3 visit

Secondary outcomes

  1. Percentage Of Participants Experiencing Complete Closure Of Their Target Wound At Month 1 And Month 2 Visits

    Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. The percentage of participants who completed target wound closure at the Month 1 and Month 2 study visits is displayed. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits.

    Time frame: From baseline to Month 1 and Month 2 visits

  2. Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit

    Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions.

    Time frame: Baseline, Month 3 visit

  3. Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit

    Total body wound burden was calculated using BSAI. A wound defined as an open area on the skin (that is, epidermal covering disrupted). BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, lower limbs, trunk \[includes groin\]), and multiplied by the weighting factor, then summed for all body regions.

    Time frame: Baseline, Month 3 visit

  4. Change From Baseline In Itching Score At Day 7

    Itching was assessed using the 5-point Itch Man Pruritus Assessment Tool. For participants up to 5 years of age, itching was assessed using caretaker's response and participants 6 years of age and older self-reported their itching assessments based on the following scores: 0=Comfortable, no itch; 1=itches a little, does not interfere with activity; 2=itches more, sometimes interferes with activity; 3=itches a lot, difficult to be still, concentrate; 4=itches most terribly, impossible to sit still or concentrate. Itching scores were categorized into 3 groups based on improvement; Improved or No Itching, Not Improved, and Missing. An itching score reduction from baseline greater than or equal to 1 point on the scale was classed as improved.

    Time frame: Baseline, Day 7

  5. Change From Baseline In Pain Score At Day 7

    Change in pain assessed at Day 7 compared to baseline was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) behavioral scale for participants 1 month to 3 years of age. Each of the 5 FLACC categories was scored from 0 to 2, which resulted in a total score between 0 and 10 with 0=Relaxed and comfortable, 1 to 3=Mild discomfort, 4 to 6=Moderate pain, and 7 to 10=Severe discomfort/pain. For participants 4 years of age and older, the "Wong Faces Pain Scale" was used. This scale shows a series of faces ranging from a happy face at 0, which represents "no hurt," to a crying face at 10, which represents "hurts worst". Pain scores were categorized into 3 groups based on improvement: Improved or No Pain, Not Improved, and Missing. A pain score reduction from baseline greater than or equal to 2 points on the scale was classed as improved.

    Time frame: Baseline, Day 7

07

Results

Posted Oct 16, 2018

Participant flow

Of 210 participants screened for this study, 169 participants were randomly assigned, on a 1:1 basis, to treatment with SD-101-6.0 or placebo at 31 study centers in 13 countries. The first participant was enrolled on 11 March 2015 and the last participant completed the study on 05 July 2017.

Participant flow — Overall Study
MilestoneSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Started8287
Received at least 1 dose of study drug8287
Completed7580
Not completed77
Withdrew: Protocol violation01
Withdrew: Returned to previous therapeutic regimen01
Withdrew: Adverse event52
Withdrew: Withdrawal by subject03
Withdrew: Elective medical treatment10
Withdrew: Non-compliance10

Outcome measures

PrimaryTime To Complete Target Wound Closure Within 3 Months

Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Time to target wound closure was measured from the date of the first administration of the study drug to the date of target wound closure. Participants were censored if they did not have a response within 3 months, or withdrew earlier before the confirmation of their target wound closing. This primary end point displays the mean time to complete target wound closure, analyzed using a Kaplan-Meier approach.

Time frame:
From baseline to Month 3 visit
Reported as:
Mean · days
Time To Complete Target Wound Closure Within 3 Months
daysSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Time To Complete Target Wound Closure Within 3 Months41.6 ± 25.5053.6 ± 28.59
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Cox Model Analysis · p = 0.985 (p-value is for Type 3 chi-square test for comparison between treatments.) · Hazard ratio (hr): 1.004 · 95% CI 0.651 to 1.549
PrimaryThe Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months

Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Participants were considered responders if they experienced complete wound closure at the Week 2 or Months 1, 2, or 3 visits. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits. This primary end point displays the percentage of participants from the ITT population who had complete target wound closure by the end of the study period (that is, 3 months). Analysis was performed on participants with post-baseline wound closure data.

Time frame:
From baseline to Month 3 visit
Reported as:
Number · percentage of participants
The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months
percentage of participantsSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months49.453.6
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Regression, Logistic · p = 0.39 (p-value is from the logistic regression model for treatment comparison.) · Odds ratio (or): 0.733 · 95% CI 0.365 to 1.474
SecondaryPercentage Of Participants Experiencing Complete Closure Of Their Target Wound At Month 1 And Month 2 Visits

Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. The percentage of participants who completed target wound closure at the Month 1 and Month 2 study visits is displayed. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits.

Time frame:
From baseline to Month 1 and Month 2 visits
Reported as:
Number · percentage of participants
Percentage Of Participants Experiencing Complete Closure Of Their Target Wound At Month 1 And Month 2 Visits
percentage of participantsSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Month 131.622.6
Month 243.042.9
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Regression, Logistic · p = 0.212 (p-value is from the logistic regression model for treatment comparison.) · Odds ratio (or): 1.633 · 95% CI 0.758 to 3.517
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Regression, Logistic · p = 0.802 (p-value is from the logistic regression model for treatment comparison.) · Odds ratio (or): 0.891 · 95% CI 0.436 to 1.821
SecondaryChange From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit

Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions.

Time frame:
Baseline, Month 3 visit
Reported as:
Least squares mean · Percentage change in BSAI
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit
Percentage change in BSAISD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit-4.637 ± 1.404-5.319 ± 1.354
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Mixed Models Analysis · p = 0.706 (The p-value is calculated based on the hypothesis testing for the difference of least-squares (LS)-means between treatment and placebo.) · Ls means difference: 0.682 · 95% CI -2.873 to 4.238
SecondaryChange From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit

Total body wound burden was calculated using BSAI. A wound defined as an open area on the skin (that is, epidermal covering disrupted). BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, lower limbs, trunk \[includes groin\]), and multiplied by the weighting factor, then summed for all body regions.

Time frame:
Baseline, Month 3 visit
Reported as:
Least squares mean · Percentage change in BSAI
Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit
Percentage change in BSAISD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit-3.050 ± 0.816-2.922 ± 0.813
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Mixed Models Analysis · p = 0.9 (The p-value is calculated based on the hypothesis testing for the difference of LS-means between treatment and placebo.) · Ls means difference: 0.128 · 95% CI -2.116 to 1.861
SecondaryChange From Baseline In Itching Score At Day 7

Itching was assessed using the 5-point Itch Man Pruritus Assessment Tool. For participants up to 5 years of age, itching was assessed using caretaker's response and participants 6 years of age and older self-reported their itching assessments based on the following scores: 0=Comfortable, no itch; 1=itches a little, does not interfere with activity; 2=itches more, sometimes interferes with activity; 3=itches a lot, difficult to be still, concentrate; 4=itches most terribly, impossible to sit still or concentrate. Itching scores were categorized into 3 groups based on improvement; Improved or No Itching, Not Improved, and Missing. An itching score reduction from baseline greater than or equal to 1 point on the scale was classed as improved.

Time frame:
Baseline, Day 7
Reported as:
Mean · units on a scale
Change From Baseline In Itching Score At Day 7
units on a scaleSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Change From Baseline In Itching Score At Day 7-0.5 ± 1.31-0.3 ± 1.24
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Regression, Logistic · p = 0.262 (p-value is from the logistic regression model for treatment comparison.) · Odds ratio (or): 1.445 · 95% CI 0.759 to 2.752
SecondaryChange From Baseline In Pain Score At Day 7

Change in pain assessed at Day 7 compared to baseline was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) behavioral scale for participants 1 month to 3 years of age. Each of the 5 FLACC categories was scored from 0 to 2, which resulted in a total score between 0 and 10 with 0=Relaxed and comfortable, 1 to 3=Mild discomfort, 4 to 6=Moderate pain, and 7 to 10=Severe discomfort/pain. For participants 4 years of age and older, the "Wong Faces Pain Scale" was used. This scale shows a series of faces ranging from a happy face at 0, which represents "no hurt," to a crying face at 10, which represents "hurts worst". Pain scores were categorized into 3 groups based on improvement: Improved or No Pain, Not Improved, and Missing. A pain score reduction from baseline greater than or equal to 2 points on the scale was classed as improved.

Time frame:
Baseline, Day 7
Reported as:
Mean · units on a scale
Change From Baseline In Pain Score At Day 7
units on a scaleSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
Change From Baseline In Pain Score At Day 7-0.3 ± 2.57-0.6 ± 3.07
Statistical analysis
  • SD-101-6.0 Cream vs Placebo (SD-101-0.0) Cream · Regression, Logistic · p = 0.098 (p-value is from the logistic regression model for treatment comparison.) · Odds ratio (or): 0.596 · 95% CI 0.323 to 1.1

Adverse events

Collected over From baseline up to 3 months.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SD-101-6.0 Cream0/82 (0%)4/82 (4.9%)49/82 (59.8%)
Placebo (SD-101-0.0) Cream1/87 (1.1%)8/87 (9.2%)46/87 (52.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
PyrexiaGeneral disorders2/820/87
InfluenzaInfections and infestations0/822/87
WoundInjury, poisoning and procedural complications1/820/87
AggressionPsychiatric disorders1/820/87
AnemiaBlood and lymphatic system disorders0/821/87
Cardiopulmonary failureCardiac disorders0/821/87
DysphagiaGastrointestinal disorders0/821/87
GastritisGastrointestinal disorders0/821/87
Oesophageal stenosisGastrointestinal disorders0/821/87
CystitisInfections and infestations0/821/87
Most frequent other events
Showing 10 of 21
Most frequent other events
EventSD-101-6.0 CreamPlacebo (SD-101-0.0) Cream
NasopharyngitisInfections and infestations11/823/87
PruritusSkin and subcutaneous tissue disorders9/828/87
PyrexiaGeneral disorders5/829/87
Skin infectionInfections and infestations3/829/87
Upper respiratory tract infectionInfections and infestations4/829/87
Wound infectionInfections and infestations6/825/87
Staphyloccocal skin infectionInfections and infestations1/826/87
CoughRespiratory, thoracic and mediastinal disorders4/824/87
PainGeneral disorders1/824/87
Ear infectionInfections and infestations1/824/87

Baseline characteristics

The Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)SD-101-6.0 CreamPlacebo (SD-101-0.0) CreamTotal
Mean13.8 ± 13.1513.9 ± 13.1213.9 ± 13.09
Sex: Female, Male
Sex: Female, Male(Participants)SD-101-6.0 CreamPlacebo (SD-101-0.0) CreamTotal
Female334881
Male493988
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SD-101-6.0 CreamPlacebo (SD-101-0.0) CreamTotal
White/Caucasian6972141
Black/African American538
Asian4812
Other112
Not Reported336
EB type
EB type(Participants)SD-101-6.0 CreamPlacebo (SD-101-0.0) CreamTotal
Simplex10818
Recessive dystrophic5762119
Junctional non-Herlitz151732
08

Study locations

38 sites
  • Phoenix, Arizona 85016, United States
  • Redwood City, California 94063, United States
  • Aurora, Colorado 80045, United States
  • Washington, District of Columbia 20016, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33155, United States
  • Chicago, Illinois 60611, United States
  • Minneapolis, Minnesota 55455, United States
  • Columbia, Missouri 65212, United States
  • Saint Louis, Missouri 63110, United States
  • Lebanon, New Hampshire 03756, United States
  • Hackensack, New Jersey 07601, United States
  • East Setauket, New York 11733, United States
  • New York, New York 10032, United States
  • Chapel Hill, North Carolina 27516, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Charleston, South Carolina 29425-5780, United States
  • Austin, Texas 78723, United States
  • San Antonio, Texas 78218, United States
  • Seattle, Washington 98105, United States
  • Kogarah, New South Wales 2217, Australia
  • Parkville, Victoria 3050, Australia
  • Parkville, Victoria 3052, Australia
  • Salzburg, 5020, Austria
  • Nice, 0-06200, France
  • Paris, 75015, France
  • Toulouse, France
  • Freiburg, Germany
  • Hannover, Germany
  • Tel Aviv, Israel
  • Milano, 20122, Italy
  • Kaunas, Lithuania
  • Groningen, 9713 GZ, Netherlands
  • Warszawa, Koszykowa, Poland
  • Belgrade, Serbia
  • Madrid, Spain
  • London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Murrell DF, Paller AS, Bodemer C, Browning J, Nikolic M, Barth JA, Lagast H, Krusinska E, Reha A; ESSENCE Study Group. Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. Orphanet J Rare Dis. 2020 Jul 21;15(1):190. doi: 10.1186/s13023-020-01435-3. PubMed 32693833 ↗
  • Paller AS, Browning J, Nikolic M, Bodemer C, Murrell DF, Lenon W, Krusinska E, Reha A, Lagast H, Barth JA; ESSENCE Study Group. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet J Rare Dis. 2020 Jun 23;15(1):158. doi: 10.1186/s13023-020-01419-3. PubMed 32576219 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Jul 2017, 27 months.

Results were first posted in Oct 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2015
First posted
Mar 10, 2015
StartActual
Mar 11, 2015
Primary completionActual
Jul 5, 2017
CompletionActual
Jul 5, 2017
Results first posted
Oct 16, 2018
Last update
Apr 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02384460
Lead sponsor
Scioderm, Inc.
Collaborators
Amicus Therapeutics
Responsible party
Sponsor
First posted
Mar 10, 2015
Start date
Mar 11, 2015
Primary completion
Jul 5, 2017
Completion
Jul 5, 2017
Results posted
Oct 16, 2018
Last update
Apr 9, 2020

Study contacts

Medical Monitor
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion